Everybody has Brugada syndrome until proven otherwise?

Viskin, Sami; Rosso, Raphaël; Friedensohn, Limor; Havakuk, Ofer; Wilde, Arthur A.M.

doi:10.1016/j.hrthm.2015.04.017

Cited by 49 publications

(34 citation statements)

References 42 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…One may recollect that in the first systematic study examining the accuracy of sodium channel blockers, none of the 53 study participants in the control group developed a type 1 Brugada pattern [9]. Nevertheless, since then several studies including various control groups have demonstrated findings more concordant with Hasdemir's results [10][11][12].…”

Section: Introductionmentioning

confidence: 79%

Brugada syndrome

Adler

2016

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

Section: Introductionmentioning

confidence: 79%

Brugada syndrome

Adler

2016

Current Opinion in Cardiology

View full text Add to dashboard Cite

show abstract

“…Recently some issues have been raised concerning the value of ajmaline in the diagnosis of BS 21. Nevertheless, patients with induced BS are at a lower arrhythmic risk but they are not risk-free.…”

Section: Discussionmentioning

confidence: 99%

Clinical characterisation and long-term prognosis of women with Brugada syndrome

Sieira

Conte

Ciconte

et al. 2016

Heart

View full text Add to dashboard Cite

show abstract

“…Some asymptomatic patients without spontaneous type 1 ECG might have false‐positive results of the SCB test 36, 37. This study included 35 asymptomatic patients with nonspontaneous type 1 ECG that was converted to type 1 ECG by the pilsicainide test (Figure 1).…”

Section: Discussionmentioning

confidence: 99%

Prognostic Significance of the Sodium Channel Blocker Test in Patients With Brugada Syndrome

Ueoka

Morita

Watanabe

et al. 2018

JAHA

View full text Add to dashboard Cite

BackgroundA drug provocation test using a sodium channel blocker (SCB) can unmask a type 1 ECG pattern in patients with Brugada syndrome. However, the prognostic value of the results of an SCB challenge is limited in patients with non–type 1 ECG. We investigated the associations of future risk for ventricular fibrillation with SCB‐induced ECG changes and ventricular tachyarrhythmias (VTAs).Methods and ResultsWe administered intravenous pilsicainide to 245 consecutive patients with Brugada syndrome (181 patients with spontaneous type 1 ECG, 64 patients with non–type 1 ECG). ECG parameters before and after the test and occurrence of drug‐induced VTAs were evaluated. During a mean follow‐up period of 113±57 months, fatal VTA events occurred in 31 patients (sudden death: n=3, ventricular tachycardia/ventricular fibrillation: n=28). Symptomatic patients and spontaneous type 1 ECG were associated with future fatal arrhythmic events. Univariable analysis of ECG parameters after the test showed that long PQ and QRS intervals, high ST level, and SCB‐induced VTAs were associated with later VTA events during follow‐up. Multivariable analysis showed that symptomatic patients, high ST level (V1) ≥0.3 mV after the test, and SCB‐induced VTAs were independent predictors for future fatal arrhythmic events (hazard ratios: 3.28, 2.80, and 3.62, 95% confidence intervals: 1.54–7.47, 1.32–6.35, and 1.64–7.75, respectively; P<0.05).Conclusions SCB‐induced VTAs and ST‐segment augmentation are associated with an increased risk of the development of ventricular tachycardia/ventricular fibrillation events during follow‐up in patients with Brugada syndrome.

show abstract

Everybody has Brugada syndrome until proven otherwise?

Cited by 49 publications

References 42 publications

Brugada syndrome

Brugada syndrome

Clinical characterisation and long-term prognosis of women with Brugada syndrome

Prognostic Significance of the Sodium Channel Blocker Test in Patients With Brugada Syndrome

Contact Info

Product

Resources

About